This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1352458507085976v1 14/5/615    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sellebjerg, F Articles by Ryder, L. P. Search for Related Content PubMed PubMed Citation Articles by Sellebjerg, F Articles by Ryder, L. P. Social Bookmarking                         What's this?

Gene expression analysis of interferon- treatment in multiple sclerosis

¹ Department of Neurology, Danish Multiple Sclerosis Research Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark;
² Department of Neurology, Danish Multiple Sclerosis Research Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; Department of Neurology, Danish Multiple Sclerosis Research Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
³ Tissue Typing Laboratory, Department of Clinical Immunology, Danish Multiple Sclerosis Research Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
⁴ Institute of Inflammation Research, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
⁵ Department of Neurology, Danish Multiple Sclerosis Research Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

^* To whom correspondence should be addressed.

	Abstract

Treatment with interferon- (IFN-) induces the expression of hundreds of genes in blood mononuclear cells, and the expression of several genes has been proposed as a marker of the effect of treatment with IFN-. However, to date no molecules have been identified that are stably induced by treatment with IFN-. We use DNA microarrays to study gene expression in 10 multiple sclerosis (MS) patients who began de novo treatment with IFN-. After the first injection of IFN-, the expression of 74 out of 3428 genes changed at least two-fold and statistically significantly (after Bonferroni correction). In contrast, we observed no persisting effects of IFN- on gene expression. Among the most strongly induced genes was MXA, which has been used in previous biomarker studies in MS. In addition, the study identified the induction of LGALS9 and TCIR1G, involved in negative regulation of T helper type I immunity and T-cell activation, as novel effects of IFN- therapy in MS.

Key Words: gene expression profiling, interferon-, microarray, multiple sclerosis

First published on April 11, 2008, doi:10.1177/1352458507085976

Multiple Sclerosis 2008;14:615.

A more recent version of this article appeared on June 1, 2008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Hesse, F. Sellebjerg, and P. S. Sorensen Absence of MxA induction by interferon {beta} in patients with MS reflects complete loss of bioactivity Neurology, August 4, 2009; 73(5): 372 - 377. [Abstract] [Full Text] [PDF]

				P. Soelberg Sorensen Review: Neutralizing antibodies against interferon-beta Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 125 - 141. [Abstract] [PDF]